(19)
(11) EP 3 247 378 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.08.2023 Bulletin 2023/34

(45) Mention of the grant of the patent:
19.07.2023 Bulletin 2023/29

(21) Application number: 16735480.2

(22) Date of filing: 08.01.2016
(51) International Patent Classification (IPC): 
C07D 498/18(2006.01)
A61P 35/00(2006.01)
A61K 31/407(2006.01)
A61K 31/436(2006.01)
C07D 491/18(2006.01)
A61K 47/62(2017.01)
A61K 31/4353(2006.01)
C12N 9/90(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/00; C07D 498/18; A61K 47/62; A61P 35/00; A61K 31/407; A61K 31/4353; A61K 31/436; C07D 491/18; C12N 9/90; C12Y 502/01008
(86) International application number:
PCT/US2016/012656
(87) International publication number:
WO 2016/112295 (14.07.2016 Gazette 2016/28)

(54)

MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF

MAKROZYKLISCHE VERBINDUNGEN MIT BETEILIGUNG AN EINER KOOPERATIVEN BINDUNG UND MEDIZINISCHE VERWENDUNGEN DAVON

COMPOSÉS MACROCYCLIQUES PARTICIPANT À UNE LIAISON COOPÉRATIVE ET LEURS UTILISATIONS MÉDICALES


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 09.01.2015 US 201562101945 P

(43) Date of publication of application:
29.11.2017 Bulletin 2017/48

(73) Proprietor: Revolution Medicines, Inc.
Redwood City, CA 94063 (US)

(72) Inventors:
  • VERDINE, Gregory, Lawrence
    Cambridge, MA 02139 (US)
  • BOWMAN, Brian, Roger
    Cambridge, MA 02139 (US)
  • SOWA, Mathew, Edward
    Brookline, MA 02445 (US)
  • BLODGETT, Joshua Alan, Van Dyke
    Cambridge, MA 02139 (US)
  • ROBISON, Keith, Earl
    Cambridge, MA 02139 (US)
  • STILES, Dylan, Talbot
    Cambridge, MA 02139 (US)
  • MORGENSTERN, Jay, Paul
    Cambridge, MA 02139 (US)
  • TOWNSON, Sharon, Ann
    Cambridge, MA 02139 (US)
  • SHIGDEL, Uddhav, Kumar
    Cambridge, MA 02139 (US)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
EP-A1- 1 079 859
WO-A2-2014/187959
WO-A1-01/36612
US-A1- 2013 072 439
   
  • DON BENJAMIN ET AL: "Rapamycin passes the torch: a new generation of mTOR inhibitors", NATURE REVIEWS. DRUG DISCOVERY, vol. 10, no. 11, 31 October 2011 (2011-10-31), pages 868-880, XP55234660, GB ISSN: 1474-1776, DOI: 10.1038/nrd3531
  • Anonymous: "SMART(TM) Drugs: Engineering Nature's Solution to the Undruggable Target Challenge", , 2016, XP55495775, Retrieved from the Internet: URL:http://www.warpdrivebio.com/docs/Warp% 20Drive%20Bio_SMART%20Drugs%20Platform_201 6.pdf [retrieved on 2018-07-27]
  • CHE, Y. ET AL.: "Inducing protein-protein interactions with molecular glues", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, pages 1-8, XP55496100, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2018.04.046
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).